Skip to content
Peptide research

Adipotide

Also known as Prohibitin-TP01 · FTPP
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic peptide designed to destroy blood vessels feeding white fat, binding prohibitin to trigger endothelial cell death, marketed for rapid fat loss. The case rests entirely on animal studies; there is no human trial evidence. The headline concern is dose-dependent kidney toxicity, documented in primates, with no long-term human safety data. Not an approved drug; human use relies on unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)

    Low

    Treated primates lost 7.4 to 14.7% body weight over 28 days; no human data exist.

  • Selective targeting of white adipose tissue vasculature without affecting lean body mass

    Low

    Mechanism confirmed in mice and primates; lean mass sparing is a secondary, less rigorous endpoint.

  • Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)

    Low

    In obese monkeys, adipotide lowered insulin AUC by 36% after four weeks of treatment.

Evidence limits

Strong preclinical evidence in mice and nonhuman primates. A single Phase 1 human trial (NCT01262664) was initiated in 2012 at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer. The trial evaluated five dose levels across a 28-day subcutaneous injection cycle. No human results have been published. The trial was terminated at the principal investigator's request; a toxicity-related reason was not established.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(13)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Dose-dependent renal tubular toxicity observed in primates

    High
  • Elevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)

    Moderate
  • Mild to marked glucosuria (glucose in urine)

    Moderate
  • Mild to moderate proteinuria (protein in urine)

    Moderate
  • Decreased serum phosphorus and potassium levels

    Moderate
  • Increased urinary renal epithelial cells indicating tubular damage

    Moderate
  • Histological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys

    Moderate
  • Mild dehydration at higher doses

    Moderate
  • Injection site reactions

    Low
  • Fatigue reported in some preclinical observations

    Theoretical
  • No long-term human safety data available — all safety data from animal studies only

    High
  • Potential off-target vascular effects in non-adipose tissues not fully characterized

    Moderate
  • Not approved for human use — any human use is entirely experimental and unregulated

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.